Molecular Glue Deals Top Billions After Revolution Medicines' Pancreatic Cancer Breakthrough
Updated
Updated · Bloomberg · May 29
Molecular Glue Deals Top Billions After Revolution Medicines' Pancreatic Cancer Breakthrough
1 articles · Updated · Bloomberg · May 29
Revolution Medicines' pancreatic cancer success has turned molecular glue drugs into one of biotech's hottest deal areas, triggering transactions worth billions of dollars.
The approach aims to attack disease-driving proteins hidden inside cells by chemically binding them to other molecules in the body, effectively disabling them.
That concept grew out of Harvard chemist Gregory Verdine's once-unconventional idea, now gaining commercial momentum after one of the biggest pancreatic cancer advances in decades.
The surge in dealmaking signals broader industry belief that molecular glues could become the next billion-dollar cancer drug class beyond this single breakthrough.
This cancer breakthrough sparked a gold rush. Beyond Revolution Medicines, who is best positioned to win the multi-billion dollar molecular glue race?
We can now target 'undruggable' proteins in cancer. What other incurable diseases could this revolutionary technology conquer next?
Daraxonrasib’s Landmark Phase 3 Results Double Survival in Metastatic Pancreatic Cancer: A New Era for RAS-Targeted Molecular Glues
Overview
Daraxonrasib has emerged as a potentially transformative treatment for patients with metastatic pancreatic ductal adenocarcinoma, a cancer with very limited options. In April 2026, Revolution Medicines announced that daraxonrasib, as a single agent, significantly improved both progression-free and overall survival compared to standard chemotherapy, even doubling overall survival. Experts have called these results a major breakthrough, noting such efficacy has not been seen in pancreatic cancer for the past 20 years. This new approach is expected to be practice-changing for physicians and to substantially improve care for patients who have progressed on prior treatments.